Nanomedicine Combats Drug Resistance in Lung Cancer

被引：44

作者：

Zheng, Xiuli ^{[1
,2
]}

Song, Xiaohai ^{[3
,4
]}

Zhu, Guonian ^{[1
,2
]}

Pan, Dayi ^{[1
,2
]}

Li, Haonan ^{[1
,2
]}

Hu, Jiankun ^{[3
,4
]}

Xiao, Kai ^{[1
,2
]}

Gong, Qiyong ^{[1
,2
,5
,6
,7
]}

Gu, Zhongwei ^{[1
,2
]}

Luo, Kui ^{[1
,2
,5
,6
]}

Li, Weimin ^{[1
,2
,5
,6
]}

机构：

[1] Sichuan Univ, West China Hosp, Huaxi MR Res Ctr HMRRC, Dept Radiol,Dept Resp, 37 Guoxue Alley, Chengdu 610041, Peoples R China

[2] Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, Crit Care Med,Inst Resp Hlth,Precis Med Ctr,State, 37 Guoxue Alley, Chengdu 610041, Peoples R China

[3] Sichuan Univ, West China Hosp, Gastr Canc Ctr, Dept Gen Surg, 37 Guoxue Alley, Chengdu 610041, Peoples R China

[4] Sichuan Univ, West China Hosp, Lab Gastr Canc, 37 Guoxue Alley, Chengdu 610041, Peoples R China

[5] Chinese Acad Med Sci, Precis Med Key Lab Sichuan Prov, Funct & Mol Imaging Key Lab Sichuan Prov, Chengdu 610041, Peoples R China

[6] Chinese Acad Med Sci, Res Unit Psychoradiol, Chengdu 610041, Peoples R China

[7] Sichuan Univ, Dept Radiol, West China Xiamen Hosp, Xiamen 361000, Fujian, Peoples R China

来源：

ADVANCED MATERIALS | 2024年 / 36卷 / 03期

基金：

中国国家自然科学基金;

关键词：

chemotherapy; drug resistance; immunotherapy; lung cancer; molecular targeted therapy; nanomedicine; radiotherapy; TUMOR-ASSOCIATED MACROPHAGES; OVERCOME CISPLATIN RESISTANCE; SOLVENT-BASED PACLITAXEL; IMMUNOGENIC CELL-DEATH; IN-VIVO DELIVERY; PHASE-II TRIAL; CO-DELIVERY; MULTIDRUG-RESISTANCE; OPEN-LABEL; ACQUIRED-RESISTANCE;

D O I：

10.1002/adma.202308977

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Lung cancer is the second most prevalent cancer and the leading cause of cancer-related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are currently available as treatment methods. However, drug resistance is a significant factor in the failure of lung cancer treatments. Novel therapeutics have been exploited to address complicated resistance mechanisms of lung cancer and the advancement of nanomedicine is extremely promising in terms of overcoming drug resistance. Nanomedicine equipped with multifunctional and tunable physiochemical properties in alignment with tumor genetic profiles can achieve precise, safe, and effective treatment while minimizing or eradicating drug resistance in cancer. Here, this work reviews the discovered resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy, and outlines novel strategies for the development of nanomedicine against drug resistance. This work focuses on engineering design, customized delivery, current challenges, and clinical translation of nanomedicine in the application of resistant lung cancer. In this review, the discovered drug resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are introduced. Recent advances of organic, inorganic, and bio-derived nanomedicines for drug-resistant lung cancer treatment are summarized. The engineering design, customized delivery, current challenges, and clinical translation of nanomedicine for lung cancer are discussed.image

引用

页数：48

共 550 条

[1] Targeting immunogenic cell death in cancer [J].